ClinicalTrials.gg
RecruitingNCT07333118Updated May 27, 2026

A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases

An Early Phase 1 interventional study of GT801 Injection in Moderate to Severe Refractory Autoimmune Disease, sponsored by Grit Biotechnology. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Grit Biotechnology · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies in Autoimmune Diseases with a site in China — 72 open to participants now, 78 under way, 7 of them phase 3. Autoimmune Diseases · China.

Planned enrollment
62nd of 113
22 · median 30
Started
2025
with 31 others
Phase 1
57 of 125
40 open now
Primary completion
2028-03
later than 54 of 77 live
Registered
108th of 125
by date
Lead sponsor
3 of 125
Grit Biotechnology

Among the 125 studies in Autoimmune Diseases with a site in China, this one is the 62nd largest by planned enrollment of the 113 interventional ones that give a count, is one of 32 that started in 2025, is one of 57 in phase 1, reaches primary completion later than 54 of the 77 other live ones, and was the 108th registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

72 of the 125 studies in Autoimmune Diseases with a site in China are open now. Recruiting first, the newest first:

66 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Autoimmune Diseases with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, open-label, dose-escalation and dose-expansion clinical trial designed to evaluate the safety, efficacy, and cellular metabolism kinetics of GT801 in the treatment of moderate-to-severe refractory autoimmune diseases. Interim analysis will be conducted when 5 patients complete primary endpoint measurement.

03

Conditions studied

  • Moderate to Severe Refractory Autoimmune Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. The participant or their legal representative voluntarily signs a written form and is willing and able to comply with the study procedures.
  • 2. Aged 18 to 65 years old (inclusive) at the time of signing the informed consent, regardless of gender.
  • 3. Participants with Systemic Lupus Erythematosus (SLE) must meet the following criteria:
  • a) Fulfill the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE.
  • b) Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2000) score ≥ 6, with at least one British Isles Lupus Assessment Group Index (BILAG-2004) Grade A (severe manifestation) or two Grade B (moderate manifestation) organ scores, or both; or SLEDAI-2000 score ≥ 8.
  • c) Meet the definition of or relapsing disease: No response to conventional treatment for more than 6 months, or disease reactivation after achieving remission. Conventional treatment is defined as the use of and cyclophosphamide plus at least one of the following immunomodulatory agents: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biological agents including rituximab, belimumab, and tabalumab.
  • 4. Participants with Idiopathic Inflammatory Myopathy (IIM) must meet the following criteria:
  • a) Fulfill the 2017 EULAR/ACR classification criteria for inflammatory myopathy (including Dermatomyositis [DM], Polymyositis [PM], Antisynthetase Syndrome [ASS], and Necrotizing Myopathy [NM]).
  • b) Positive for myositis-specific antibodies or myositis-associated antibodies.
  • c) Must have moderate to severe IIM at screening, defined as Manual Muscle Testing-8 (MMT-8) score ≥ 142, or MMT-8 score \< 142 plus meeting 2 of the following criteria:
  • 1) Physician Global Assessment (PGA) (Visual Analog Scale [VAS]) ≥ 2 cm (on a 10-cm VAS).
  • 2) Patient Global Assessment (PtGA) (VAS) ≥ 2 cm (on a 10-cm VAS).
  • 3) Health Assessment Questionnaire (HAQ) score > 0.25.
  • 4) Elevation of one or more muscle enzymes (creatine kinase [CK], lactate dehydrogenase [LDH], [AST], alanine aminotransferase [ALT]) ≥ 1.5 × (ULN).
  • d) Meet the definition of refractory/relapsing or progressive disease:
  • 1) Refractory/relapsing: No response to conventional treatment for more than 6 months, or disease reactivation after achieving remission. Conventional treatment is defined as the use of glucocorticoids and cyclophosphamide plus at least one of the following immunomodulatory agents: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biological agents including rituximab, belimumab, and tabalumab.
  • 2) Progressive: Development of worsening myositis or rapidly progressive interstitial lung disease.
  • 5. Participants with Systemic Sclerosis (SSc) must meet the following criteria:
  • a). Fulfill the 2013 American College of Rheumatology (ACR) classification criteria for SSc.
  • b). Positive for SSc-related autoantibodies.
  • c). Meet the definition of refractory/relapsing or progressive disease:
  • 1) Refractory/relapsing: No response to conventional treatment for more than 6 months, or disease reactivation after achieving remission. Conventional treatment is defined as the use of glucocorticoids and cyclophosphamide plus at least one of the following immunomodulatory agents: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biological agents including rituximab, belimumab, and tabalumab.
  • 2) Refractory/relapsing: No response to conventional treatment for more than 6 months, or disease reactivation after achieving remission. Conventional treatment is defined as the use of glucocorticoids and cyclophosphamide plus at least one of the following immunomodulatory agents: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biological agents including rituximab, belimumab, and tabalumab.
  • 6. Participants with ANCA-Associated Vasculitis (AAV) must meet the following criteria:
  • a). Fulfill the 2022 ACR/EULAR classification criteria for ANCA-associated vasculitis, including Microscopic Polyangiitis (MPA), Granulomatosis with Polyangiitis (GPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA).
  • b). Positive for ANCA-related antibodies (myeloperoxidase-ANCA [MPO-ANCA] or proteinase 3-ANCA [PR3-ANCA]).
  • c). Birmingham Vasculitis Activity Score (BVAS) ≥ 15 points (total score: 63 points), indicating active vasculitis.
  • d). Meet the definition of refractory/relapsing disease: No response to conventional treatment for more than 6 months, or disease reactivation after achieving remission. Conventional treatment is defined as the use of glucocorticoids and cyclophosphamide plus at least one of the following immunomodulatory agents: antimalarials, azathioprine, methotrexate, leflunomide, tacrolimus, cyclosporine, and biological agents including rituximab, belimumab, and tabalumab.
  • 7. Participants with Sjogren's Syndrome must meet the following criteria:
  • a). Fulfill the 2002 American-European Consensus Group (AECG) criteria for primary Sjogren's Syndrome or the 2016 ACR/EULAR classification criteria.
  • b). EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) score ≥ 6.
  • c). Positive for anti-SSA/Ro antibodies.
  • d). Meet the definition of refractory/relapsing disease: No response to conventional treatment for more than 6 months, or disease reactivation after achieving remission. Conventional treatment is defined as the use of glucocorticoids and cyclophosphamide plus at least one of the following immunomodulatory agents: antimalarials, azathioprine, methotrexate, leflunomide, tacrolimus, cyclosporine, and biological agents including rituximab, belimumab, and tabalumab.
  • 8. Laboratory test results at screening must meet the following criteria (excluding indicators related to the study disease):
  • a). ≥ 1.5 × 10⁹/L.
  • b). ≥ 80 g/L; count ≥ 50 × 10⁹/L.
  • c). Alanine Aminotransferase (ALT) ≤ 3 × ULN; Aspartate Aminotransferase (AST) ≤ 3 × ULN (unless elevations of ALT and/or AST are assessed by the investigator to be related to Polymyositis [PM] or Dermatomyositis [DM]); Total (TBIL) \< 2 × ULN (for participants with Gilbert's syndrome, Direct Bilirubin [DBIL] ≤ 1.5 × ULN).
  • d). rate ≥ 30 mL/min.
  • e). (APTT) ≤ 1.5 × ULN; Prothrombin Time (PT) ≤ 1.5 × ULN.
  • f). (LVEF) ≥ 50% confirmed by echocardiography, with no (ECG) abnormalities detected.
  • g). Baseline oxygen saturation > 92% measured on room air.
  • 9. Women of must:
  • a). Have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result at screening, confirmed by the investigator.
  • b). Agree to avoid breastfeeding during study participation until at least 1 year after GT801 injection or until GT801 cells are no longer detectable by two consecutive flow cytometry tests, whichever is later.
  • c). Male participants with sexual partners and female participants of childbearing potential must agree to use highly effective methods (e.g., oral contraceptives, intrauterine devices, or condoms) starting from screening until at least 1 year after GT801 injection or until GT801 cells are no longer detectable by two consecutive flow cytometry tests, whichever is later. Male participants must agree to use condoms during sexual contact with pregnant women or women of childbearing potential for at least 1 year after GT801 injection, even after successful vasectomy.

Exclusion criteria

Exclusion Criteria:

  • 1. Participants with SLE
  • a. Drug-induced systemic lupus erythematosus.
  • b. Participants with lupus crisis; or those with concurrent diseases requiring the use of protocol-prohibited drugs, who are deemed ineligible for enrollment by the investigator.
  • 2. Participants with IIM
  • a. Documented inclusion body myositis (IBM), drug-induced polymyositis (PM) or dermatomyositis (DM), -associated PM or DM, or non-inflammatory myopathies (e.g., muscular dystrophy).
  • b. Uncontrolled extramuscular disease manifestations related to PM or DM:
  • 1) ILD: Forced vital capacity (FVC) \< 55% or requirement for oxygen therapy.
  • 2) Severe dysphagia manifestations that, in the investigator's judgment, would increase the participant's risk of participating in the clinical trial.
  • 3) Severe cardiac manifestations (e.g., congestive heart failure, cardiac arrhythmia, conduction abnormalities requiring treatment, or myocardial infarction) that, in the investigator's judgment, would increase the participant's risk of participating in the clinical trial.
  • 3. Participants with SSc
  • a. Severe SSc-associated pulmonary arterial hypertension (PAH) that is uncontrollable with medical treatment.
  • b. Rapidly progressive SSc-related lower gastrointestinal tract (small and large intestine) involvement requiring parenteral nutrition; active gastric antral vascular ectasia.
  • c. Uncontrolled or rapidly progressive ILD with oxygen saturation (SaO₂) \< 92% (on room air at rest); or requirement for mechanical ventilation support within 1 year prior to signing the form.
  • 4. Participants with ANCA-Associated Vasculitis (AAV)
  • a. Presence of rapidly progressive glomerulonephritis, acute mononeuritis multiplex, or central nervous system (CNS) involvement unrelated to AAV at screening.
  • b. Life-threatening severe vasculitis (including diffuse alveolar hemorrhage, respiratory failure, intestinal perforation or massive hemorrhage, cerebral vasculitis, cardiac vasculitis, etc.).
  • c. Secondary vasculitis (e.g., systemic lupus erythematosus, Henoch-Schönlein purpura, drug-induced, malignancy-related, infection-related, primary immunodeficiency, etc.).
  • 5. Participants with Sjögren's Syndrome (SS)
  • a. Presence of poorly controlled severe systemic primary Sjögren's disease (pSjD) manifestations at baseline that, in the investigator's assessment, would place the participant at excessive risk, including pSjD-associated cytopenia of Grade ≥ 2 per the (CTCAE).
  • b. Secondary Sjögren's syndrome with a primary diagnosis of other confirmed diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and inflammatory bowel disease).
  • c. Regular use of medications known to cause xerostomia/keratoconjunctivitis sicca (a common major side effect).
  • d. Concomitant diseases that may interfere with the efficacy assessment of primary Sjögren's syndrome, e.g., inflammatory bowel disease, gout, sarcoidosis, amyloidosis, , IgG4-related disease, etc.

All Participants:

  • 6. History of severe reactions or allergies.
  • 7. Detection of pre-existing anti-polyethylene glycol (anti-PEG) antibodies in the body prior to GT801 infusion.
  • 8. to or hypersensitivity reactions to any component of the product.
  • 9. History of the following cardiac diseases:
  • a. (NYHA) Class III or IV congestive heart failure.
  • b. Myocardial infarction or coronary artery bypass grafting within 6 months prior to screening.
  • c. History of ventricular arrhythmia or unexplained syncope not caused by vasovagal response or dehydration; or interval (QTc) > 480 ms at screening; history of severe non-ischemic cardiomyopathy.
  • 10. History of any active malignancy or malignant tumor within 5 years prior to screening, except for the following conditions: early-stage tumors treated with curative intent (carcinoma in situ or Stage I tumors, non-ulcerative primary melanoma with depth \< 1 mm and no lymph node involvement), basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, or ductal carcinoma in situ of the breast that has undergone potentially curative treatment.
  • 11. Any other known autoimmune diseases besides the study disease.
  • 12. Long-term use of anticoagulant drugs that affect coagulation function.
  • 13. Clinically significant bleeding symptoms or confirmed bleeding tendency within 6 months prior to screening (e.g., gastrointestinal bleeding, hemorrhagic gastric ulcer, etc.); hereditary or acquired bleeding and thrombotic tendencies (e.g., hemophilia, coagulation disorders, hypersplenism, etc.); arterial or venous thrombotic events within 6 months prior to screening (e.g., cerebrovascular diseases including cerebral hemorrhage and cerebral infarction, deep vein thrombosis, and/or pulmonary embolism).
  • 14. Presence of severe underlying medical conditions at screening, such as:
  • a. Evidence of uncontrolled viral, bacterial, fungal, or other infections requiring systemic intravenous therapy.
  • b. Clear clinical evidence of dementia or altered mental status.
  • c. History of any other central nervous system diseases or neurodegenerative disorders (e.g., epilepsy, convulsions, paralysis, aphasia, stroke, severe traumatic brain injury, dementia, Parkinson's disease, psychosis).
  • 15. Positive results for any of the following tests:
  • a. (HIV) antibody positive.
  • b. surface antigen (HBsAg) positive; or hepatitis B core antibody (HBcAb) positive with hepatitis B virus (HBV)-DNA levels above the lower limit of quantification of the assay.
  • c. virus (HCV) antibody positive with HCV RNA levels above the lower limit of quantification of the assay.
  • d. Syphilis antibody positive (excluding false-positive results caused by underlying diseases).
  • 16. Positive results for cytomegalovirus (CMV) DNA or Epstein-Barr virus (EBV) DNA testing.
  • 17. Active tuberculosis or latent tuberculosis that has not received appropriate treatment prior to screening.
  • 18. Receipt of other investigational drugs within 4 weeks prior to signing the informed consent form (ICF); or the interval between the ICF signing date and the last dose of the previous clinical trial participation is still within 5 half-lives of the drug, whichever is longer.
  • 19. Receipt of plasma exchange therapy or immunoadsorption therapy within 4 weeks prior to investigational product administration.
  • 20. Receipt of B-cell-targeted drug therapy within 1 week prior to investigational product administration, including but not limited to rituximab, belimumab, tabalumab, etc.
  • 21. Receipt of biologic therapy such as anti-TNF-α antibodies within 12 weeks prior to investigational product administration.
  • 22. Use of tacrolimus, cyclosporine, azathioprine, mycophenolate mofetil, mycophenolic acid, methotrexate, etc., within 2 weeks prior to investigational product administration.
  • 23. Receipt of neonatal Fc receptor (FcRn) antagonist therapy (e.g., efgartigimod, etc.) within 3 weeks prior to investigational product administration.
  • 24. Receipt of complement inhibition therapy (e.g., eculizumab, etc.) within 3 weeks prior to investigational product administration.
  • 25. Vaccination with or mRNA vaccines within 8 weeks prior to enrollment; or inactivated vaccines within 4 weeks prior to enrollment.
  • 26. Major surgery within 8 weeks prior to screening, or planned surgery during the study period.
  • 27. History of organ transplantation.
  • 28. Prior receipt of chimeric antigen receptor T-cell (CAR-T) therapy targeting any antigen.
  • 29. Presence of any conditions that, in the investigator's judgment, would prevent the participant from completing the entire trial, confound trial results, or make trial participation not in the participant's best interest.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    GT801 Injection treatment group

    GT801 Injection

    Biological: GT801 Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants experiencing dose limiting toxicity

    The proportion of participants with dose-limiting toxicity (DLT) occurring within 28 days after infusion

    Time frame: 28 days post GT801 infusion

  2. Adverse Events (AEs) occurring after infusion and their proportions

    Adverse Events (AEs) occurring after infusion and their proportions

    Time frame: 3 months post GT801 infusion

Secondary outcomes

  1. Efficacy outcomes for Systemic Lupus Erythematosus (SLE)

    SLE Response index 4(SRI-4) response: Min/Max Value: Not specified; a decrease in score indicates improvement, higher scores indicate worse outcome

    Time frame: 1, 2, 3 and 6 Months post GT801 infusion, with an interim analysis at 3 months.

  2. Efficacy outcomes for Idiopathic Inflammatory Myopathies (IIM)

    Total lmprovement Score (TlS): Min/Max Value: Not specified; an increase in score indicates improvement, higher scores indicate better outcome.

    Time frame: 1, 2, 3 and 6 Months post GT801 infusion, with an interim analysis at 3 months.

  3. Efficacy outcomes for Systemic Sclerosis (SSc)

    Combined Response Index in Systemic Sclerosis (CRISS): the score ranges from 0 to 1 point; a score ≥ 0.6 indicates treatment improvement, while a score \< 0.6 indicates no disease improvement.

    Time frame: 1, 2, 3 and 6 Months post GT801 infusion, with an interim analysis at 3 months.

  4. Efficacy Outcomes for ANCA-Associated Vasculitis (AAV)

    The proportion of subjects achieving complete remission and partial remission

    Time frame: 1, 2, 3 and 6 Months post GT801 infusion, with an interim analysis at 3 months.

  5. Efficacy Outcomes for Participants with Sjogren's Syndrome

    ESSDAI response rates

    Time frame: 1, 2, 3 and 6 Months post GT801 infusion, with an interim analysis at 3 months.

  6. Efficacy Outcomes for Participants with Sjogren's Syndrome

    ESSPRI response rates

    Time frame: 1, 2, 3 and 6 Months post GT801 infusion, with an interim analysis at 3 months.

  7. Cellular and mRNA Kinetics of All Participants: Time to Peak Expansion of CAR+ Cells After Infusion (Tmax)

    Time to Peak Expansion (Tmax) refers to the time point at which the CAR+ cells proliferate to the peak quantity in the participants' bodies post infusion.

    Time frame: From infusion to 12 months

  8. Cellular and mRNA Kinetics of All Participants: Expansion Peak of CAR+ Cells After Infusion (Cmax)

    Expansion Peak (Cmax) refers to the maximum quantity of CAR+ cells achieved in the participants' bodies post infusion.

    Time frame: From infusion to 12 months

  9. Cellular Kinetics of All Participants: Area Under the Curve (AUC) of CAR+ Cells After Infusion

    Area Under the Curve (AUC) refers to the area enclosed by the curve of CAR+ cell quantity change over time after infusion and the time axis.

    Time frame: From infusion to 12 months

  10. Cellular and mRNA Kinetics of All Participants: Duration of Detectable Concentration of CAR+ Cells After Infusion (Tlast)

    Duration of Detectable Concentration (Tlast) refers to the time period from the infusion of GT801 to the last time point at which the CAR+ cells can be detected in the peripheral blood or target tissues.

    Time frame: From infusion to 12 months

  11. Pharmacodynamic characteristics in participants for all participants

    Monitor serum cytokine levels after infusion

    Time frame: From infusion to 2 months

Other outcomes

  1. Exploration of Peripheral Blood Lymphocyte Subsets and B Lymphocyte Subsets: Changes in T Cells and NK Cells

    Determination of the counts of T cells and NK cells

    Time frame: 1, 3, 6, 9 Months post GT801 infusion

  2. Exploration of Peripheral Blood Lymphocyte Subsets and B Lymphocyte Subsets: Duration of B-Cell Depletion

    Determination of B-cell counts and calculation of the duration of B-cell count reduction

    Time frame: 3, 6, 9 Months post GT801 infusion, with an interim analysis at 3 months.

  3. Exploration and analysis of BCR repertoire diversity via BCR sequencing

    Detection of BCR diversity on B cells via sequencing

    Time frame: 1, 3, 6, 9 Months post GT801 infusion, with an interim analysis at 3 months.

  4. Pathological changes of involved organs before and after treatment

    Pathological examination of lesion tissue biopsies was performed to observe the changes in histopathological characteristics after treatment compared with those before treatment, such as fibrosis, vascular lesions, and inflammatory cell infiltration.

    Time frame: From GT801 infusion to 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2028, 28 months after the start.

Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's planned 28 months is above that.

Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Jan 12, 2026
StartActual
Nov 7, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07333118
Lead sponsor
Grit Biotechnology
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Nov 7, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
May 27, 2026

Study contacts

Huji Xu
Contact
xuhuji@smmu.edu.cn
+8613671609764

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GT801

Start the discussion